App aims to tame chemo side effects in breast cancer
NCT ID NCT05425550
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a digital health app called medidux™ in 196 people with HER2-positive breast cancer. The app was used for up to 16 weeks during chemotherapy to help track and manage side effects. The goal was to see if using the app reduced the number of severe side effects. However, the study was terminated early, so we have limited data on how well it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- medidux™ digital health application
- What this could lead to
- If it works, this app could help patients and doctors better track and manage chemotherapy side effects, potentially reducing severe complications.
- What could go wrong
- The study was terminated early, so results are limited. The app is a supportive tool, not a treatment, and its benefit over standard care is unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seespital Horgen-Onkologie
Horgen, 8810, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?